Hepatocellular carcinoma
Conditions
Interventions
experimental group:Lenvatinib combined with TACE
Sponsors
The First Affiliated Hospital of Zhejiang University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. The patients who have no history of targeted drug therapy such as sorafenib and lovatinib, and no history of lovatinib allergy agree to receive lovatinib and TACE treatment; 2. Patients with HBsAg positive for more than 3 months; 3. Patients with unresectable liver cancer who have not received other systematic treatment in the late stage; 4. Patients older than 18 and younger than 75; 5. Patients with good blood pressure control (= 6 months; 9. The functions of blood, liver and kidney meet the following conditions: (discharge standard) Neutrophil count >= 1.5 x 10^9 / L. Platelet count >= 75 x 10^9 / L. Hemoglobin concentration >= 8.5g/dl. Serum albumin concentration >= 2.8g/dl. Bilirubin is 3 times lower than the normal upper limit. AST and ALT were 5 times lower than the normal upper limit, ALP was 4 times lower than the normal upper limit. The prothrombin time was prolonged within 6 seconds. Creatinine was 1.5 times lower than the normal upper limit.
Exclusion criteria
Exclusion criteria: 1. Patients whose liver occupied more than 50% of the liver volume; 2. Patients with liver cancer invading the main portal vein or inferior vena cava; 3. Patients with rupture and bleeding of liver cancer; 4. Patients with extrahepatic metastasis of liver cancer; 5. Patients with previous history of hepatic encephalopathy, refractory ascites or gastroesophageal varices; 6. Patients with contraindications to TACE, such as portosystemic shunt, extrahepatic blood flow, obvious atherosclerosis; 7. Patients who are allergic to intravenous contrast media; 8. Pregnant or lactating women or subjects with family planning within two years; 9. Patients with HIV and syphilis infection; 10. Patients with other malignancies or with other malignancies within 5 years before admission; 11. Patients with severe cardiac, renal and other organ dysfunction; 12. Patients with active clinical severe infection > Level 2 (NCI-CTC version 4); 13. Patients with mental disorders may affect informed consent; 14. Patients unable to take oral medicine; 15. Patients who participated in clinical trials of other drugs within 12 months before admission.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| TTUP; | — |
Secondary
| Measure | Time frame |
|---|---|
| PFS;OS;ORR;quality-of-life measurements; | — |
Countries
China
Contacts
Public ContactChunhui Nie
The First Affiliated Hospital of Zhejiang University
Outcome results
None listed